Prompted by recent findings on the amplification of c-erbB-2 (HER-2, neu) oncogene in salivary gland tumours, the present study was conducted to analyse the expression of c-erbB-2 in both benign and malignant salivary gland tumours, with special emphasis on its prognostic significance and relevance to clinical data. A series of 219 salivary gland tumours (with pertinent clinical data), including 103 malignant and 116 benign tumours, were analysed immunohistochemically using a monoclonal antibody to c-erbB-2 protein. Smoking was not a risk factor for malignant tumours, smokers being equally represented in both groups: 18.4 and 21.6% in malignant and benign series, respectively. Multi-variate analysis of the extensive clinical data did not disclose any other risk factors either. Cellular membrane staining for c-erbB-2 was present in 36 (35.0%) carcinomas and 41 (35.3%) benign tumours. Among the malignant tumours, c-erbB-2 expression was most frequent in adenoid cystic carcinomas (57.7%) followed by adenocarcinomas (39.3%). Among the benign tumours, 47% of Warthin’s tumours and 33.3% of the pleomorphic adenomas showed staining for c-erbB-2. The highest prevalence of c-erbB-2 immunoreactivity was seen in adenocarcinomas of the parotid gland (81.8%), followed by undifferentiated carcinomas (75%) and adenoid cystic carcinomas (73.3%) in that location. Age at diagnosis, number of recurrences, analysis as well as time to relapse or metastases were similar in c-erbB-2-positive and -negative malignant tumours. Also mortality in c-erbB-2-positive and -negative salivary gland cancers was similar. The results indicate that c-erbB-2 protein expression is frequently present in both malignant and benign salivary tumours. Although weakly associated with some clinically relevant parameters, the expression of this oncoprotein seems to be of limited use as a prognostic determinant in salivary gland tumours.

Keywords:
c-erbB-2 oncogene, Salivary gland tumours, Recurrence, Prognosis
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.